

Clinical Pharmacy Program Guidelines for Sublingual Immunotherapy (SLIT)

Program	Prior Authorization- Sublingual Immunotherapy (SLIT)
Medication	Sublingual Immunotherapy (SLIT) – Grastek (Timothy grass pollen allergen extract), Odactra (<i>Dermatophagoides farinae/Dermatophagoides pteronyssinus</i> allergen extract), Oralair (Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens allergen extract), Ragwitek (Short Ragweed Pollen allergen extract)
Markets in Scope	Arizona, California, Hawaii, Maryland, Nevada, New Jersey, New York, New York EPP, Pennsylvania- CHIP, Rhode Island, South Carolina
Issue Date	5/2014
Pharmacy and Therapeutics Approval Date	3/2020
Effective Date	5/2020

1. Background:

The sublingual immunotherapy (SLIT) medications are indicated for patients who have symptoms of allergic rhinitis with natural exposure to allergens and who demonstrate specific IgE antibodies to the relevant allergen. Grastek (Timothy grass pollen allergen extract) and Oralair (Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens allergen extract) are indicated for patients with grass pollen-induced allergic rhinitis, Ragwitek (short ragweed pollen allergen extract) is indicated for ragweed pollen-induced allergic rhinitis and Odactra (*Dermatophagoides farinae/Dermatophagoides pteronyssinus* allergen extract) is indicated for house dust mite (HDM)-induced allergic rhinitis.

Candidates for allergen immunotherapy are patients whose symptoms are not adequately controlled by medications, and avoidance measures have been ineffective. In addition, patients experiencing unacceptable adverse effects of medications or who wish to reduce the long term use of medications may also be candidates for immunotherapy.

2. Coverage Criteria:

<p>A. <u>Grastek</u></p> <p>1. <u>Initial Authorization</u></p> <p>a. Grastek will be approved based on all of the following:</p> <p>(1) Diagnosis of moderate to severe grass pollen-induced allergic rhinitis</p>

-AND-

- (2) Diagnosis confirmed by **one** of the following:
- a. Positive skin test to Timothy grass or cross-reactive grass pollens (eg, Sweet Vernal, Orchard/Cocksfoot, Perennial Rye, Kentucky blue/June grass, Meadow Fescue, or Redtop)
 - b. *in vitro* testing for pollen-specific IgE antibodies for Timothy grass or cross-reactive grass pollens (e.g., Sweet Vernal, Orchard/Cocksfoot, Perennial Rye, Kentucky blue/June grass, Meadow Fescue, or Redtop)

-AND-

- (3) Treatment is started or will be started at least 12 weeks before the beginning of the grass pollen season

-AND-

- (4) History of failure, contraindication, or intolerance to **two** of the following:
- a. oral antihistamine [e.g. cetirizine (Zyrtec)]
 - b. intranasal antihistamine [e.g. azelastine (Astelin)]
 - c. intranasal corticosteroid [e.g. fluticasone (Flonase)]
 - d. leukotriene inhibitor [e.g. montelukast (Singulair)]

-AND-

- (5) Not received in combination with similar cross-reactive grass pollen immunotherapy (e.g., Oralair)

-AND-

- (6) Patient does not have unstable and/or uncontrolled asthma

-AND-

- (7) Prescribed by or in consultation with a specialist in allergy and immunology

Authorization will be issued for 12 months

2. Reauthorization

a. **Grastek** will be approved based on the following criterion:

- (1) Documentation of positive clinical response to Grastek therapy

Authorization will be issued for 12 months.

B. Oralair

1. Initial Authorization

a. **Oralair** will be approved based on **all** of the following:

- (1) Diagnosis of moderate to severe grass pollen-induced allergic rhinitis

-AND-

- (2) Diagnosis confirmed by **one** of the following:

- a. Positive skin test to any of the five grass species contained in Oralair [(i.e., Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue grass mixed pollens) or cross-reactive grass pollens (e.g., Cocksfoot, Meadow Fescue, or Redtop)]
- b. *in vitro* testing for pollen-specific IgE antibodies for any of the five grass species contained in Oralair [(i.e., Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue grass mixed pollens) or cross-reactive grass pollens (e.g., Cocksfoot, Meadow Fescue, or Redtop)]

-AND-

- (3) Treatment is started or will be started at least 4 months before the beginning of the grass pollen season

-AND-

- (4) History of failure, contraindication, or intolerance to **two** of the following:

- a. oral antihistamine [e.g. cetirizine (Zyrtec)]
- b. intranasal antihistamine [e.g. azelastine (Astelin)]
- c. intranasal corticosteroid [e.g. fluticasone (Flonase)]
- d. leukotriene inhibitor [e.g. montelukast (Singulair)]

-AND-

- (5) Not received in combination with similar cross-reactive grass pollen immunotherapy (e.g., Grastek)

-AND-

- (6) Patient does not have unstable and/or uncontrolled asthma

-AND-

- (7) Prescribed by or in consultation with a specialist in allergy and immunology

Authorization will be issued for 12 months.

2. Reauthorization

- a. **Oralair** will be approved based on the following criterion:

- (1) Documentation of positive clinical response to Oralair therapy

Authorization will be issued for 12 months.

C. Ragwitek

1. Initial Authorization

- a. **Ragwitek** will be approved based on **all** of the following:

- (1) Diagnosis of moderate to severe short ragweed pollen-induced allergic rhinitis

-AND-

- (2) Diagnosis confirmed by **one** of the following:

- a. Positive skin test to short ragweed pollen
b. *in vitro* testing for pollen-specific IgE antibodies for short ragweed pollen

-AND-

- (3) Treatment is started or will be started at least 12 weeks before the

beginning of the short ragweed pollen season

-AND-

- (4) History of failure, contraindication, or intolerance to **two** of the following:
- a. oral antihistamine [e.g. cetirizine (Zyrtec)]
 - b. intranasal antihistamine [e.g. azelastine (Astelin)]
 - c. intranasal corticosteroid [e.g. fluticasone (Flonase)]
 - d. leukotriene inhibitor [e.g. montelukast (Singulair)]

-AND-

- (5) Patient does not have unstable and/or uncontrolled asthma

-AND-

- (6) Prescribed by or in consultation with a specialist in allergy and immunology

Authorization will be issued for 12 months.

2. Reauthorization

- a. **Ragwitek** will be approved based on the following criterion:

- (1) Documentation of positive clinical response to Ragwitek therapy

Authorization will be issued for 12 months.

D. Odactra

1. Initial Authorization

- a. **Odactra** will be approved based on **all** of the following:

- (1) Diagnosis of house dust mite (HDM)-induced allergic rhinitis.

-AND-

- (2) Diagnosis confirmed by **one** of the following:

- (a) Positive skin test to licensed house dust mite allergen extracts
- (b) *in vitro* testing for IgE antibodies to *Dermatophagoides farinae* or

Dermatophagoides pteronyssinus house dust mites

-AND-

- (3) History of failure, contraindication, or intolerance to **two** of the following:
- oral antihistamine [e.g. cetirizine (Zyrtec)]
 - intranasal antihistamine [e.g. azelastine (Astelin)]
 - intranasal corticosteroid [e.g. fluticasone (Flonase)]
 - leukotriene inhibitor [e.g. montelukast (Singulair)]

-AND-

- (4) Patient does not have unstable and/or uncontrolled asthma

-AND-

- (5) Prescribed by or in consultation with a specialist in allergy and immunology

Authorization will be issued for 12 months.

2. Reauthorization

- a. **Oductra** will be approved based on the following criterion:

- (1) Documentation of positive clinical response to Oductra therapy

Authorization will be issued for 12 months.

3. Additional Clinical Rules:

- Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic. Use of automated approval and re-approval processes varies by program and/or therapeutic class.
- Supply limits may be in place.

4. References:

1. Grastek® [package insert]. Catalent Pharma Solutions Limited, Blagrove Swindon, Wiltshire, UK. December 2019.

Confidential and Proprietary, © 2020 UnitedHealthcare Services Inc.

2. Oralair® [package insert]. Greer Laboratories, Inc. Lenoir, NC. January 2016.
3. Ragwitek® [package insert]. Catalent Pharma Solutions Limited, Blagrove Swindon, Wiltshire, UK. June 2019.
4. Ocactra® [package insert]. Catalent Pharma Solutions Limited, Blagrove, Swindon, Wiltshire, UK. April 2017.
5. Cox, L, Nelson, H, Lockey, R, et al. Allergen immunotherapy: A practice parameter third update. American Academy of Allergy, Asthma & Immunology. December 2010.
6. Treatment of seasonal allergic rhinitis: An evidence-based focused 2017 guideline update. Dykewicz MS, Wallace DV, Baroody F, et.al. *Ann Allergy Asthma Immunol.* 2017 Dec;119(6):489-511.e41
7. Sublingual immunotherapy: A focused allergen immunotherapy practice parameter update. Greenhawt M, Oppenheimer J, Nelson M, et.al. *Ann Allergy Asthma Immunol.* 2017 Mar;118(3):276-82.e2.

Program	Program Type- Prior Authorization
Change Control	
Date	Change
5/2014	New Program
5/2015	Administrative changes and updates to references.
4/2016	Removed SCIT requirement, removed allergen avoidance, updated specialist prescriber requirement. References updated.
4/2017	Odactra added to criteria. Added examples of drugs to step through. Updated policy template.
3/2018	Annual review. Updated background and references.
3/2019	Annual review with administrative changes. Modified symptomatic asthma to severe, unstable and/or uncontrolled asthma.
3/2020	Annual review. Updated references.